Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease

AL002 - Alector, AbbVie

Brady Burgess; Jingjing Gao; Arthur J Mayorga; Tuan Nguyen; Gary Romano; Giacomo Salvadore,

Jun 20, 2024